Category Archives: Stem Cell Human Trials

CHICAGO--(BUSINESS WIRE)-- OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL. Vantictumab is a first-in-class antibody that has broad anti-cancer stem cell and anti-tumor activity in patient-derived xenograft tumor models. The presentation at ASCO (Abstract 2540), entitled First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the Wnt pathway in a Phase I study for patients with advanced solid tumors, was the first clinical presentation of this novel agent. Dr. David Smith (University of Michigan Cancer Center at Ann Arbor, MI) presented the data on behalf of the other principal investigators (Dr. Lee Rosen at the University of California, Los Angeles, CA, and Dr. Kyriakos Papadopoulos at The START Center for Cancer Care, San Antonio, TX) and the entire study team. In the ongoing trial of 24 patients, vantictumab was generally well tolerated up to the current dose of 10 mg/kg every three weeks. A bone protection strategy has been successful in ensuring bone health. … Continue reading →

The licence will allow scientists to attempt to manufacture blood on an industrial scale The world's first human trials of synthetic blood will take place in Scotland. Researchers from the Scottish Centre for Regenerative Medicine in Edinburgh have been granted a licence to make blood from stem cells that can be tested on humans. The licence from the UK's Medicines and Healthcare Products Regulatory Agency will allow scientists at SCRM to attempt to manufacture blood on an industrial scale. The research is designed to help to tackle shortages and stop the transfer of infections from blood donors. The trials on humans will be the first stage in establishing more large-scale clinical trials and could result in regular use of synthetic blood. Researchers will use stem cells from adult donors - known as induced pluripotent stem cells - as part of this project instead of the more controversial embryotic ones. Project leader Professor Marc Turner said: "In the first part of the project we used human embryonic stem cell lines," He said: "one of the problems with using those lines is you can't choose what the blood group is going to be." Professor Turner said: "Over the last few years there … Continue reading →

Scotland may host human trials of synthetic blood Saturday, June 01, 2013 By Press Association Reporter The worlds first human trials of synthetic blood could take place in Scotland, it has been reported. The licence from the UKs Medicines and Healthcare products Regulatory Agency will allow scientists at SCRM to attempt to manufacture blood on an industrial scale which will help to tackle shortages and stop the transfer of infections from blood donors, according to the paper. Trials on humans, if approved, would be the first stage in establishing more large-scale clinical trials and could result in regular use of synthetic blood. Researchers will use stem cells from adult donors known as induced pluripotent stem cells as part of this project instead of the more controversial embryotic ones. Project leader Marc Turner said: In the first part of the project we used human embryonic stem cell lines and one of the problems with using those lines is you cant choose what the blood group is going to be. Over the last few years there has been a lot of work on induced pluripotent stem cells, and with those an adult can donate a small piece of skin or a blood … Continue reading →

Pioneering blood trials 'agreed' The world's first human trials of synthetic blood will take place in Scotland, it has been reported. Researchers from the Scottish Centre for Regenerative Medicine (SCRM) in Edinburgh have been granted a licence to make blood from stem cells which can be tested on humans, the Scotsman has reported. The licence from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) will allow scientists at SCRM to attempt to manufacture blood on an industrial scale which will help to tackle shortages and stop the transfer of infections from blood donors, according to the paper. These trials on humans will be the first stage in establishing more large-scale clinical trials and could result in regular use of synthetic blood. Researchers will use stem cells from adult donors - known as induced pluripotent stem cells - as part of this project instead of the more controversial embryotic ones. Project leader Marc Turner said: "In the first part of the project we used human embryonic stem cell lines and one of the problems with using those lines is you can't choose what the blood group is going to be. Over the last few years there has been a lot … Continue reading →

May 30 2013 The world's first human trials of synthetic blood could take place in Scotland, it has been reported. Researchers from the Scottish Centre for Regenerative Medicine (SCRM) in Edinburgh have been granted a licence to make blood from stem cells which could be tested on humans, The Scotsman has reported. The licence from the UK's Medicines and Healthcare products Regulatory Agency will allow scientists at SCRM to attempt to manufacture blood on an industrial scale which will help to tackle shortages and stop the transfer of infections from blood donors, according to the paper. Trials on humans, if approved, would be the first stage in establishing more large-scale clinical trials and could result in regular use of synthetic blood. Researchers will use stem cells from adult donors - known as induced pluripotent stem cells - as part of this project instead of the more controversial embryotic ones. Project leader Marc Turner said: "In the first part of the project we used human embryonic stem cell lines and one of the problems with using those lines is you can't choose what the blood group is going to be. "Over the last few years there has been a lot of … Continue reading →

The world's first human trials of synthetic blood will take place in Scotland, it has been reported. Researchers from the Scottish Centre for Regenerative Medicine (SCRM) in Edinburgh have been granted a licence to make blood from stem cells which can be tested on humans, The Scotsman has reported. The licence from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) will allow scientists at SCRM to attempt to manufacture blood on an industrial scale which will help to tackle shortages and stop the transfer of infections from blood donors, according to the paper. These trials on humans will be the first stage in establishing more large-scale clinical trials and could result in regular use of synthetic blood. Researchers will use stem cells from adult donors - known as induced pluripotent stem cells - as part of this project instead of the more controversial embryotic ones. Project leader Marc Turner said: "In the first part of the project we used human embryonic stem cell lines and one of the problems with using those lines is you can't choose what the blood group is going to be. "Over the last few years there has been a lot of work on induced … Continue reading →

The world's first human trials of synthetic blood could take place in Scotland, it has been reported. Researchers from the Scottish Centre for Regenerative Medicine (SCRM) in Edinburgh have been granted a licence to make blood from stem cells which could be tested on humans, The Scotsman has reported. The licence from the UK's Medicines and Healthcare products Regulatory Agency will allow scientists at SCRM to attempt to manufacture blood on an industrial scale which will help to tackle shortages and stop the transfer of infections from blood donors, according to the paper. Trials on humans, if approved, would be the first stage in establishing more large-scale clinical trials and could result in regular use of synthetic blood. Researchers will use stem cells from adult donors - known as induced pluripotent stem cells - as part of this project instead of the more controversial embryotic ones. Project leader Marc Turner said: "In the first part of the project we used human embryonic stem cell lines and one of the problems with using those lines is you can't choose what the blood group is going to be. "Over the last few years there has been a lot of work on induced … Continue reading →

May 28, 2013 Brett Smith for redOrbit.com Your Universe Online For years, stem-cell based therapies have been described as a potential way to treat spinal cord injuries in humans, and a new study published in the journal Stem Cell Research and Therapy describes an exciting step forward in that pursuit. According to the report, a single injection of human stem cells was able to induce neuronal regeneration and improved mobility in rats that were afflicted with a severe spinal cord injury. This is exciting, especially because, historically, there has been very little to offer patients with acute spinal cord injury, said co-author Dr. Joseph Ciacci, chief of neurosurgery for the Veterans Affairs San Diego Healthcare System. The research team observed as the injected rats regained motor skills and experienced a loss of the uncontrollable muscle spasms typically associated with traumatic spinal cord injury.The stem cell therapy also improved the integrity of the spine, allowing for signals to pass through the injury location. The primary benefits were improvement in the positioning and control of paws during walking tests and suppression of muscle spasticity, said Dr. Martin Marsala, a medical doctor and professor at the University of California, San Diego and a … Continue reading →

human trials By: bigreeg1089 … Continue reading →

By Caleb Hellerman, CNN updated 9:58 AM EDT, Fri May 24, 2013 STORY HIGHLIGHTS Editor's note: "Life's Work" features innovators and pioneers who are making a difference in the world of medicine. (CNN) -- Dr. Roberto Bolli's face lights up when he talks about his true love: the human heart. "The heart is really a miraculous organ. It beats 72 times a minute throughout our life, which means billions of times in our lifetime. And it never gets tired," Bolli says. "It knows exactly how much blood to pump; it can increase its output by fivefold if we need more oxygen -- for example, if we're running or doing strenuous activity. You have 5 billion cells called myocites, all beating in synchrony, in a perfectly coordinated manner, to maximize the heart's pumping ability. It is an engineering feat that never ceases to amaze me." Bolli was born in Perugia, Italy, the son of a general practitioner. He came to the United States after finishing medical school in Italy, starting at Baylor College of Medicine in Houston. Since 1994, he's been the chief of cardiology at the University of Louisville, where he also directs the Institute of Molecular Cardiology. Like most … Continue reading →